Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug perturbation RNA sequencing of 2 prostate cancer cell lines

ABSTRACT: Drug perturbation RNA sequencing of 2 prostate cancer cell lines

PROVIDER: PRJNA821516 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19981900.fastq.gz	Fastqsanger.gz
	SRR19982000.fastq.gz	Fastqsanger.gz
	SRR19982100.fastq.gz	Fastqsanger.gz
	SRR19982200.fastq.gz	Fastqsanger.gz
	SRR19982300.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1728

Similar Datasets

Drug perturbation RNA sequencing of 2 prostate cancer cell lines

Project description:Prioritizing cancer treatments at the individual patient level remains challenging, and performing co-clinical studies using patient-derived models in real-time is often not unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework to predict and validate drug sensitivity sensitivity in both a human tumors and in its their pre-existing high est-fidelity (cognate) (cognate) model(s)—for contextual in vivo validation—) by leveraging perturbational profiles of clinically-relevant oncology drugs. As proof-of-concept, we applied OncoLoop to prostate cancer (PCa) using a series of genetically engineered mouse models (GEMMs) that capture the broad spectrum of disease states, including metastatic, castration-resistant, metastatic, and neuroendocrine prostate cancer. Interrogation of published cohorts revealed that most patients were represented by at least one cognate GEMM-derived tumor (GEMM-DT), based on upon Master Regulator (MR) conservation analysis. Drugs recurrently predicted to recurrently invert MR protein activity in patients and their cognate GEMM-DTs were successfully validated, including in two cognate allografts and one cognate patient derived xenograft (PDX). OncoLoop is highly generalizable and can be extended to other cancers and potentially other pathologdiseasesies.

2022-10-31 | GSE199800 | GEO

Proteomic characterization of Prostate cancer cell lines

Project description:Proteomic characterization of prostate cancer cell lines after drug treatment.

2022-10-13 | PXD029525 | Pride

RNA-sequencing of prostate cancer xenografts, their 3D cultures and prostate cancer cell-lines.

Project description:RNA-sequencing of prostate cancer xenografts, their 3D cultures and prostate cancer cell-lines.

2021-09-29 | E-MTAB-9930 | biostudies-arrayexpress

Profiles of prostate cancer cell lines

Project description:Profiles of prostate cancer cell lines

| PRJNA343724 | ENA

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development (aCGH)

Project description:Prostate cancer discovery and translational research are hampered by a lack of preclinical models which accurately reproduce the biological heterogeneity observed in patients. Accordingly, we have established a bank of transplantable patient-derived prostate tumor xenograft lines, using subrenal capsule grafting of human tumor tissue into immuno-deficient mice. This panel includes the first lines generated from primary prostate cancer tissue, and also new lines from metastatic tissue. Critically, the lines retained salient features of the original patient tumors, including histopathology, clinical marker expression, chromosomal aberration and gene expression profiles. Furthermore, they span major histopathological and molecular subtypes of prostate cancer, capturing diverse inter- and intra-tumoral heterogeneity. Host castration led to the development of castrate-resistant tumors, including the first model of complete neuroendocrine transdifferentiation. This publicly-available resource provides novel tools to advance mechanistic understanding of disease progression and response to therapy, and delivers clinically-relevant model systems for evaluation of preclinical drug efficacy. 3 primary tumors and 21 xenograft tumors

2013-01-12 | E-GEOD-41188 | biostudies-arrayexpress

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development (expression)

2013-01-12 | E-GEOD-41192 | biostudies-arrayexpress

human prostate cell lines

Project description:human prostate cell lines

| PRJNA622489 | ENA

RNA-sequencing of prostate cancer xenografts, their 3D cultures and prostate cancer cell-lines.

Project description:RNA-sequencing of prostate cancer xenografts, their 3D cultures and prostate cancer cell-lines.

| PRJEB42165 | ENA

MITF perturbation in A2058 Melanoma cell lines

Project description:MITF perturbation in A2058 Melanoma cell lines

| PRJNA704810 | ENA